Stada and Xbrane Add Two To Biosimilar Development Alliance
Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.
You may also be interested in...
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Stada’s owner has revealed plans to squeeze out the German firm’s remaining minority shareholders.
Through a partnership with Stada, Sweden’s Xbrane is looking to introduce a biosimilar to Lucentis in major developed markets, including the EU and the US, where the hunt for a commercialization partner continues.